Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Idera Pharmaceutical (IDRA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 72,027
  • Shares Outstanding, K 27,181
  • Annual Sales, $ 900 K
  • Annual Income, $ -65,980 K
  • 36-Month Beta 2.64
  • Price/Sales 91.72
  • Price/Cash Flow N/A
  • Price/Book 0.95

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/18
See More
  • Average Estimate -0.49
  • Number of Estimates 4
  • High Estimate -0.45
  • Low Estimate -0.56
  • Prior Year -0.64
  • Growth Rate Est. (year over year) +23.44%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.25 +17.78%
on 01/24/19
3.18 -16.67%
on 01/16/19
-0.25 (-8.62%)
since 01/15/19
3-Month
2.25 +17.78%
on 01/24/19
7.59 -65.09%
on 11/26/18
-4.82 (-64.52%)
since 11/15/18
52-Week
2.25 +17.78%
on 01/24/19
17.12 -84.52%
on 05/31/18
-12.63 (-82.66%)
since 02/15/18

Most Recent Stories

More News
Idera Pharmaceuticals to Present at the 37th Annual J.P. Morgan Healthcare Conference

Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) today announced that the company will present at the 37 Annual J.P. Morgan Healthcare Conference on Wednesday, January 9, 2019 at 8:30 a.m. Pacific Time (11:30...

JPM : 105.55 (+3.06%)
IDRA : 2.65 (+1.53%)
Idera Pharmaceuticals Announces Appointment of Carol A. Schafer to its Board of Directors

Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) today announced that Carol A. Schafer joined its Board of Directors, effective December 18, 2018.

LXRX : 5.35 (+4.49%)
WFC : 49.22 (+1.44%)
IDRA : 2.65 (+1.53%)
Idera Pharmaceuticals Presents Clinical Safety and Efficacy Update from the ILLUMINATE-204 Trial of the Combination of Tilsotolimod and Ipilimumab for Unresectable or Metastatic Melanoma Following Failure of PD-1 Inhibitor Treatment

- 32.4% of patients evaluable for efficacy achieved partial response or better; 76.5% of patients achieved disease control -

IDRA : 2.65 (+1.53%)
Idera Pharmaceuticals to Provide ILLUMINATE-204 Clinical Data Update on Friday, December 14, 2018

Idera Pharmaceuticals, Inc. (NASDAQ: IDRA), a clinical-stage biopharmaceutical company focused on the development and ultimate commercialization of drug candidates for both oncology and rare disease indications...

IDRA : 2.65 (+1.53%)
United Parcel Service, Endurance International Group, Idera Pharmaceuticals, Aptevo Therapeutics, and Electro Scientific Industries -- Future Expectations, Projections Moving into 2018

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Mercer International Inc. (NASDAQ:MERC),...

SCND : 4.4500 (+2.30%)
ESIO : 29.99 (-0.03%)
EIGI : 7.40 (+0.14%)
APVO : 1.62 (-2.41%)
IDRA : 2.65 (+1.53%)
UPS : 110.87 (-0.83%)
MERC : 14.98 (+0.07%)
Idera Pharmaceuticals (IDRA) Reports Q3 Loss, Lags Revenue Estimates

Idera (IDRA) delivered earnings and revenue surprises of 17.86% and -93.05%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

IDRA : 2.65 (+1.53%)
Idera: 3Q Earnings Snapshot

EXTON, Pa. (AP) _ Idera Pharmaceuticals Inc. (IDRA) on Tuesday reported a loss of $11.6 million in its third quarter.

IDRA : 2.65 (+1.53%)
Idera Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Corporate Update

- Company to Provide ILLUMINATE 204 Data Update in the First Half of December 2018 -

IDRA : 2.65 (+1.53%)
Idera Pharmaceuticals (IDRA) Q3 Earnings Preview: What to Expect

Idera (IDRA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

IDRA : 2.65 (+1.53%)
Idera Pharmaceuticals Presents Data from the ILLUMINATE-204 Trial of the Combination of Tilsotolimod and Ipilimumab for Unresectable or Metastatic Melanoma Following Failure of PD-1 Inhibitor Treatment at the 2018 European Society for Medical Oncology (ESMO) Congress

- Key findings presented in poster discussion demonstrate clear abscopal effect of intratumoral tilsotolimod -

IDRA : 2.65 (+1.53%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

See More Share

Trade IDRA with:

Business Summary

Idera Pharmaceuticals, Inc. is a drug discovery and development company that is developing drug candidates to treat cancer and infectious, respiratory, and autoimmune diseases, and for use in combination with therapeutic and prophylactic vaccines. Idera's proprietary drug candidates are designed to modulate...

See More

Key Turning Points

2nd Resistance Point 2.79
1st Resistance Point 2.72
Last Price 2.65
1st Support Level 2.59
2nd Support Level 2.54

See More

52-Week High 17.12
Fibonacci 61.8% 11.44
Fibonacci 50% 9.69
Fibonacci 38.2% 7.93
Last Price 2.65
52-Week Low 2.25

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar